002932，重大资产重组！

Core Viewpoint - Mingde Biological has signed a framework agreement with Bluefan Medical to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd., marking a significant asset restructuring initiative aimed at enhancing its emergency medical services business [1][3][4]. Group 1: Transaction Details - The transaction is expected to constitute a major asset restructuring as defined by the regulations, and it will be executed in cash without involving a share issuance or changing the controlling shareholder [3][4]. - The target company specializes in emergency rescue products, particularly first aid kits, and has a strong presence in both industrial and consumer markets [3][4]. Group 2: Strategic Importance - This acquisition aligns with Mingde Biological's strategic focus on the critical care sector, allowing for an integrated approach to emergency diagnosis and treatment, thereby enhancing its market position [4]. - The integration of product lines and customer bases between Mingde Biological and the target company is expected to create a synergistic ecosystem that spans diagnosis, protection, and treatment [4]. Group 3: Current Status and Market Information - The transaction is still in the planning stage, with ongoing negotiations and due diligence, and the final terms will be established in a formal acquisition agreement [4][5]. - As of the latest market data, Mingde Biological's stock price is reported at 17.82 yuan per share, with a total market capitalization of 4.144 billion yuan [6].